Fixed-dose combination and chronic kidney disease progression: Which is the best?

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 450-455

  Hopkins, Keith A ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

goals; hypertension; kidney; therapy; treatment

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; METHYLDOPA; NEBIVOLOL; NONDIHYDROPYRIDINE; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DIURETICS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; KIDNEY DISEASES; MEDICATION ADHERENCE; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN;

EID: 77955924787     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833b9771     Document Type: Review

References (34)

1. World Health Statistics 2009. http://www.who.int/whosis/whostat/EN-WHS09- Full.pdf. [Last accessed 14 April 2010].
2. Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol 2006; 22:553-555.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
4. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
5. Izzo JL, Black HR, Sica DA. Systemic hemodynamics and regional blood flow regulation. In: Izzo JL, Sica DA, Black HR, Council for High Blood Pressure Research (American Heart Association), editors. Hypertension primer: the essentials of high blood pressure: basic science, population science, and clinical management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. pp. 36-44.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
8. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
10. Russell M, Fleg JL, Galloway WJ, et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J 2006; 152:867-875.
11. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008-2013.
12. Zannad F. Managing hypertension: a question of STRATHE. J Hum Hypertens 2005; 19 (Suppl 1):S3-S7.
13. Gradman AH, Weir MR, Bakris GL. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich) 2008; 10:398-405.
14. Wald DS, LawM, Morris JK, etal. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290-300.
15. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62:443-462.
16. Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29:972-984.
17. Scisney-MatlockM,Bosworth HB, GigerJN, etal. Strategies for implementing and sustaining therapeutic lifestyle changes as part of hypertension management in African Americans. Postgrad Med 2009; 121:147-159.
18. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.
19. Yoshimura M, Kawai M. Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin- aldosterone system. J Renin Angiotensin Aldosterone Syst 2010 [Epub ahead of print].
20. Kerr EA, Zikmund-Fisher BJ, Klamerus ML, et al. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med 2008; 148:717-727.
21. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4:42-50.
22. Myers MG, Leenen FH. Persistence of the antihypertensive effect of low-dose combination therapy in mild hypertension. Blood Press 2006; 15:325-332.
23. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008; 10:185-194.
24. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
25. Epstein BJ, Roberts ME. Managing peripheral edema in patients with arterial hypertension. Am J Ther 2009; 16:543-553.
26. Poulter NR, Wedel H, Dahlof B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (AS-COT-BPLA). Lancet 2005; 366:907-913.
27. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173-1181.
28. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221-229.
29. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
30. Guerrero P, Fuchs FD, Moreira LM, etal. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens 2008; 30:553-564.
31. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418-424.
32. Yusuf S,TeoKK, Pogue J, etal. Telmisartan, ramipril,orboth in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
33. Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20:807-815.
34. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53:646-653.